Mauro Di Pilato, Ph.D.

Peer-Reviewed Articles

1. Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, Sivakumar R, Cianciaruso C, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell 184(17):4512-4530.e22, 2021. e-Pub 2021. PMID: 34343496.
2. Di Pilato M, Palomino-Segura M, Mejías-Pérez E, Gómez CE, Rubio-Ponce A, D'Antuono R, Pizzagalli DU, Pérez P, Kfuri-Rubens R, Benguría A, Dopazo A, Ballesteros I, Sorzano COS, Hidalgo A, Esteban M, Gonzalez SF. Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection. NPJ Vaccines 6(1):52, 2021. e-Pub 2021. PMID: 33846352.
3. Di Pilato M, Kim EY, Cadilha BL, Prüßmann JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V, Carrizosa E, Mani V, Ligorio M, Warner RD, Medoff BD, Marangoni F, Villani AC, Mempel TR. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature 570(7759):112-116, 2019. e-Pub 2019. PMID: 31092922.
4. Di Pilato M, Mejías-Pérez E, Sorzano COS, Esteban M. Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response. J Virol 91(13):e00575-17, 2017. e-Pub 2017. PMID: 28424281.